BRAF and plexiform neurofibroma: The more potent allosteric MEKi trametinib is approved for adult BRAF V600E mutant cancers and is also currently undergoing evaluation in both refractory low-grade gliomas and plexiform neurofibromas (NCT03363217, NCT02124772) [26, 27].